Please login to the form below

Not currently logged in
Email:
Password:

Good results for Novartis cancer drug

A major Phase III clinical trail into new cancer drug, everolimus (RAD001), was halted by the presiding independent data monitoring committee.

A major Phase III clinical trail into new cancer drug, everolimus (RAD001), was halted by the presiding independent data monitoring committee.

Interim results showed that patients with kidney cancer who received the drug benefited from significantly better progression free survival than if they had been taking a placebo.

The committee stopped the study because it had met the conditions for its primary endpoint.

Everolimus was developed by pharma company Novartis as a once-daily oral therapy to treat cancer.

Daniel Vasella, chairman and CEO of Novartis, said: "Everolimus has the potential to greatly help patients with kidney cancer, especially in advanced stages, who up to now have had no treatment options, as patients in the clinical trail on everolimus experienced a significantly longer period of time during which their cancer did not progress."

"Everolimus is a targeted therapy which is being studied in multiple tumour types, and could provide significant benefit to patients suffering from cancer."

The drug provides a substantial reduction in the progression of kidney cancer by inhibiting the mTOR protein, a central regulator of tumour cell division and blood vessel growth in cancer cells.

David Epstein, president and CEO of Novartis Oncology, said: "This progression-free survival benefit demonstrates the possibilities of continuous mTOR inhibition as a promising target in oncology."

3rd March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics